Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.74 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2752627 | 0.86 | ALDH1A1 (0.76) | KMT2AMEN1ALDH1A1RAB9ANPSR1 | |
| SCHEMBL17107156 | 0.82 | ALDH1A1 (0.79) | KMT2AMEN1ALDH1A1RAB9ANPSR1 | |
| SCHEMBL10810440 | 0.81 | ALOX5 (0.76) | KMT2AMEN1ALDH1A1RAB9ANPSR1 | |
| SCHEMBL205687 | 0.80 | KMT2A (0.67) | KMT2AMEN1ALDH1A1RAB9ANPSR1 | |
| SCHEMBL15086878 | 0.79 | ALOX5 (0.74) | KMT2AMEN1ALDH1A1RAB9ANPSR1 | |
| SCHEMBL2753568 | 0.79 | ADORA3 (0.73) | KMT2AMEN1ALDH1A1RAB9ANPSR1 | |
| SCHEMBL31665058 | 0.79 | RAB9A (0.65) | KMT2AMEN1ALDH1A1RAB9ANPSR1 | |
| SCHEMBL12248914 | 0.79 | ALDH1A1 (0.66) | KMT2AMEN1ALDH1A1RAB9ANPSR1 | |
| SCHEMBL18588881 | 0.79 | MEN1 (0.65) | KMT2AMEN1ALDH1A1RAB9ANPSR1 | |
| SCHEMBL16017437 | 0.79 | MEN1 (0.65) | KMT2AMEN1ALDH1A1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170290814-A1 | METHODS OF TREATMENT OF CHOLESTASIS AND FIBROSIS | GENFIT (FR) | 2017-10-12 | — | — | US | claimed |
| WO-2017178174-A1 | METHODS OF TREATMENT OF CHOLESTASIS AND FIBROSIS | GENFIT (FR) | 2017-10-19 | — | — | WO | disclosed |
| US-20170290814-A1 | METHODS OF TREATMENT OF CHOLESTASIS AND FIBROSIS | GENFIT (FR) | 2017-10-12 | — | — | US | disclosed |
| US-20170290814-A1 | METHODS OF TREATMENT OF CHOLESTASIS AND FIBROSIS | GENFIT (FR) | 2017-10-12 | — | — | US | disclosed |
| US-20170290814-A1 | METHODS OF TREATMENT OF CHOLESTASIS AND FIBROSIS | GENFIT (FR) | 2017-10-12 | — | — | US | disclosed |
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | Sourthern Research Institute Office of Commercialization and Intellectual Prop. (US) | 2013-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085133-A1 | ANTI-VIRAL TREATMENT AND ASSAY TO SCREENFOR ANTI-VIRAL AGENT | MAVS, SNRPE, LONP1 | KMT2A 4174/4885MEN1 1632/4885ALDH1A1 3082/4885 |
| US-20170290814-A1 | METHODS OF TREATMENT OF CHOLESTASIS AND FIBROSIS | NR1H4, SLC10A1, MMP1 | KMT2A 4164/4885MEN1 4583/4885ALDH1A1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.